Literature DB >> 6979449

Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.

T Sakurai, T Fujita, I Kono, T Kabashima, K Yamane, N Tamura, H Kashiwagi.   

Abstract

The capacity of complement-mediated solubilization of immune complexes (complex releasing activity: CRA) was studied in 63 sera from eight systemic lupus erythematosus (SLE) patients. CRA in sera of active SLE (35 +/- 17.%) was significantly lower than that of inactive SLE (64.1 +/- 24.1%, P less than 0.001). In addition, 20 of 23 sera collected during active diseases demonstrated CRA values less than 50% of the control pooled serum. On the other hand, CRA of 29 of 40 sera from inactive disease exceeded the 50% level. CRA in SLE sera correlated with complement component levels and in particular with the CH50. Serial determination of CRA and of levels of circulating immune complexes (CIC), C4 and C3 in two active patients indicated that the correlation between CRA and the complement components was positive, while that between CRA and CIC was negative. These studies provide evidence that CRA may be useful for following the activity of SLE and that CRA reflects the levels of the complement components of both classical and alternative pathways. The possibility that CIC may be solubilized and opsonized by complement and cleared by the reticuloendothelial system was discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979449      PMCID: PMC1536587     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  A new complement function: solubilization of antigen-antibody aggregates.

Authors:  G W Miller; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Immunologic factors and clinical activity in systemic lupus erythematosus.

Authors:  P H Schur; J Sandson
Journal:  N Engl J Med       Date:  1968-03-07       Impact factor: 91.245

Review 4.  Mechanism of solubilization of immune aggregates by complement. Implications for immunopathology.

Authors:  M Takahashi; J Czop; A Ferreira; V Nussenzweig
Journal:  Transplant Rev       Date:  1976

5.  Physicochemical and functional relationships of immune complexes.

Authors:  M Mannik
Journal:  J Invest Dermatol       Date:  1980-05       Impact factor: 8.551

Review 6.  Solubilization of antigen-antibody complexes: a new function of complement as a regulator of immune reactions.

Authors:  M Takahashi; S Takahashi; S Hirose
Journal:  Prog Allergy       Date:  1980

7.  The role of complement in the binding and degradation of immunoglobulin aggregates by macrophages.

Authors:  A Kijlstra; L A van Es; M R Daha
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

8.  The effect of complement on the ingestion of soluble antigen-antibody complexes and IgM aggregates by mouse peritoneal macrophages.

Authors:  J L van Snick; P L Masson
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

9.  C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum.

Authors:  A T Sobel; V A Bokisch; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

10.  Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.

Authors:  M Takahashi; B F Tack; V Nussenzweig
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

View more
  9 in total

1.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

2.  Complement-mediated solubilization of immune complexes. Solubilization inhibition and complement factor levels in SLE patients.

Authors:  G Baatrup; I Petersen; E Kappelgaard; H H Jepsen; S E Svehag
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

Review 3.  Factors influencing immune complex localisation.

Authors:  L Schrieber; R Penny
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

4.  A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.

Authors:  N A Mooney; F C Hay; T A Poulton
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

5.  Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.

Authors:  G Baatrup; I Petersen; J C Jensenius; S E Svehag
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

6.  Inhibition of immune complex solubilization by sera of patients with membranoproliferative glomerulonephritis.

Authors:  T R Welch; A Kleesattel; L Beischel
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

7.  Solubilization of intraglomerular deposits of IgG immune complexes by human sera or gamma-globulin in patients with lupus nephritis.

Authors:  Y Tomino; H Sakai; M Takaya; M Miura; T Suga; M Endoh; Y Nomoto
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

Review 8.  Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions.

Authors:  Robert Root-Bernstein
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

Review 9.  Circadian Clock and Complement Immune System-Complementary Control of Physiology and Pathology?

Authors:  Pooja Shivshankar; Baharan Fekry; Kristin Eckel-Mahan; Rick A Wetsel
Journal:  Front Cell Infect Microbiol       Date:  2020-08-14       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.